ReviewScience translational medicine2012
Merging systems biology with pharmacodynamics.
Review in Science translational medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 153 citations in OpenAlex.
- Quantitative Systems Pharmacology (QSP): Bridging Biology and Mechanism with Clinical Drug Development Decisions.Journal of clinical pharmacology · 2026Review
- The integration of machine learning into traditional Chinese medicine.Journal of pharmaceutical analysis · 2025Review
- QSP Modeling Shows Pathological Synergism Between Insulin Resistance and Amyloid-Beta Exposure in Upregulating VCAM1 Expression at the BBB Endothelium.CPT: pharmacometrics & systems pharmacology · 2025Article
- Systems immunology: When systems biology meets immunology.Frontiers in immunology · 2025Review
- Bridging systems biology and tissue engineering: Unleashing the full potential of complex 3DBiophysics reviews · 2024Review
- Towards systems immunology of critical illness at scale: from single cell 'omics to digital twins.Trends in immunology · 2023Review
- What's next for computational systems biology?Frontiers in systems biology · 2023Review
- Predicting individual-specific cardiotoxicity responses induced by tyrosine kinase inhibitors.Frontiers in pharmacology · 2023Article
- Accelerating robust plausible virtual patient cohort generation by substituting ODE simulations with parameter space mapping.Journal of pharmacokinetics and pharmacodynamics · 2022Article
- Neuroprotective Effects of the Psychoactive Compound Biatractylolide (BD) in Alzheimer's Disease.Molecules (Basel, Switzerland) · 2022Article
- New Drug Development and Clinical Trial Design by Applying Genomic Information Management.Pharmaceutics · 2022Review
- Artificial intelligence to deep learning: machine intelligence approach for drug discovery.Molecular diversity · 2021Review
- Virtual metabolic human dynamic model for pathological analysis and therapy design for diabetes.iScience · 2021Article
- Wenxin Keli for the Treatment of Arrhythmia-Systems Pharmacology andFrontiers in pharmacology · 2021Article
- Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids.Pharmacological reviews · 2020Review
- Mechanistic Computational Models of MicroRNA-Mediated Signaling Networks in Human Diseases.International journal of molecular sciences · 2019Review
- Harnessing Human Microphysiology Systems as Key Experimental Models for Quantitative Systems Pharmacology.Handbook of experimental pharmacology · 2019Article
- Network Pharmacology Deciphering Mechanisms of Volatiles ofEvidence-based complementary and alternative medicine : eCAM · 2019Article
- Dynamic Targeting in Cancer Treatment.Frontiers in physiology · 2019Article
- Cognitive Impairment in Chronic Obstructive Pulmonary Disease (COPD): Possible Utility of Marine Bioactive Compounds.Marine drugs · 2018Review
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
The emerging discipline of systems pharmacology aims to combine analysis and computational modeling of cellular regulatory networks with quantitative pharmacology approaches to drive the drug discovery processes, predict rare adverse events, and catalyze the practice of personalized precision medicine. Here, we introduce the concept of enhanced pharmacodynamic (ePD) models, which synergistically combine the desirable features of systems biology and current PD models within the framework of ordinary or partial differential equations. ePD models that analyze regulatory networks involved in drug action can account for a drug's multiple targets and for the effects of genomic, epigenomic, and posttranslational changes on the drug efficacy. This new knowledge can drive drug discovery and shape precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.